Abstract 23P
Background
The heterogeneous nature of luminal breast cancer alters the patients’ response to the treatment. Despite the proven success of endocrine therapy, not all patients respond, or substantially, those who initially responded might develop endocrine resistance. It is necessary to determine novel anti-cancer agents to be used as a combination with the standard endocrine therapy regimens. Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are present at a high frequency in advanced ER+ breast cancer. Developing synthetic lethality (SL)-based therapeutic strategies for ARID1A-mutated breast cancer holds promise.
Methods
Here we first confirmed the effect of ARID1A knockout on endocrine therapeutic response in ER+ breast cancer in vitro. The effect on cell proliferation, viability, apoptosis, and EMT was evaluated. The synthetic lethal partner of ARID1A in breast cancer cell lines was identified using SLIdR (Synthetic Lethal Identification in R), a rank-based statistical method for predicting SL pairs from large-scale perturbation screens, The effect of genetic perturbations of RHEB on cell proliferation, apoptosis, and endocrine therapy response was evaluated in ARID1A-deficient BRCA cells compared to control cells. These results were further confirmed in ARID1A-mutated T47D cells.
Results
In vitro proliferation and viability assays confirmed increased proliferation of ARID1A KO MCF7 cells on endocrine treatment. ARID1A KO cells also promoted EMT. RHEB (Ras Homolog, MTORC1 Binding) was identified as the synthetic lethality pair of ARID1A in breast cancer cell lines. Genetic perturbations of RHEB showed that targeting RHEB selectively inhibit the growth of ARID1A-deficient BRCA cells. Moreover, knockout of RHEB in T47D cells, a breast cancer cell line carrying an ARID1A somatic mutation, significantly impaired cell proliferation, triggers apoptosis and led to susceptibility to endocrine therapy compared to control cells.
Conclusions
This study shows a novel synthetic lethality interaction between ARID1A-RHEB and hypothesizes that the development of small molecule inhibitors of RHEB that selectively inhibits the activation of mTORC1 might represent a novel strategy for treating BRCA with ARID1A loss-of-function mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
86P - Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
Presenter: Noé Herbel
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Clinical features and genetic profile of MDM2-altered solid tumors
Presenter: Julia Tejerina-Peces
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluation of trending drug targets and technologies in current drug development
Presenter: Matteo Repetto
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
Presenter: Jacopo Uliano
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Molecular predictors of response to the therapy with mitotane in adrenocortical cancer
Presenter: Erika Porubayeva
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - Circulating cell-free DNA fragmentation profiles during systemic therapy of advanced-stage non-small cell lung cancer patients
Presenter: Jelena Milovanovic
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Targeted therapy in pediatric acute myeloid leukemia: An unmet need
Presenter: Banda Teja
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Anticancer activity of Inula recemosa root extract in human liver cancer cell line by attenuation of OCT4/Sox2 axis
Presenter: Tania Ghosh(Sarkar)
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
Presenter: James Korolewicz
Session: Cocktail & Poster Display session
Resources:
Abstract